ConvaTec Group Plc
Statement regarding the ConvaTec Annual General Meeting due to
COVID-19
READING, UNITED KINGDOM (2 April 2020)
In light of the rapidly evolving events of the COVID-19 outbreak, the Directors of ConvaTec Group Plc (the "Company") have made the decision to hold the Company's 2020 Annual General Meeting ("AGM" or "Meeting") in the form of a hybrid meeting, which will allow shareholders to attend and participate in the Meeting electronically.
In furtherance of this decision, the AGM will no longer be held at The Roseate Reading Hotel, but will instead take place on 7 May 2020 at 11am, at the Company's registered office, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH. We ask that shareholders do not attend the meeting in person, but instead join the Meeting remotely.
Information and instructions, detailing how shareholders may attend and participate in the Meeting electronically can be found on our website at, www.convatecgroup.com/investors , where we will also provide shareholders with further information in relation to the AGM, should it be necessary to do so.
A printed copy of the aforementioned information and instructions will be posted to shareholders who elect to receive hard copies of documentation.
The well-being of our shareholders is vitally important to us and we recommend that shareholders adhere to the current instructions from the Government and Public Health England's advice to stay at home. We encourage shareholders to vote on the resolutions proposed within the Notice of Meeting by completion of the Form of Proxy or by electronic means, further details of which can be found in the Notice of Meeting. Please note the deadline for submitting proxies will be 11am on Tuesday 5 May 2020.
Enquiries
Analysts and Investors
Mark Reynolds, Director Investor Relations, ConvaTec +44 (0)7551 036 625
Media
Buchanan: Charles Ryland / Chris Lane / Vicky Haynes +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.